Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
Ashwani Verma Maintained (AXSM) at Strong Buy with Decreased Target to $105 on, Aug 6th, 2024
Ashwani Verma of UBS, Maintained "Axsome Therapeutics, Inc." (AXSM) at Strong Buy with Decreased Target from $107 to $105 on, Aug 6th, 2024.
Ashwani has made no other calls on AXSM in the last 4 months.
There are 5 other peers that have a rating on AXSM. Out of the 5 peers that are also analyzing AXSM, 0 agree with Ashwani's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Ashwani
- Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $107 on, Friday, July 26th, 2024
- Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $106 on, Wednesday, June 12th, 2024
- Joel Beatty of "Baird" Maintained at Buy with Increased Target to $112 on, Tuesday, May 7th, 2024
- David Hoang of "Citigroup" Maintained at Strong Buy with Decreased Target to $125 on, Tuesday, May 7th, 2024
- Vikram Purohit of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $115 on, Monday, April 29th, 2024
